Across the 23 companies analyzed in this year's report, more than US$200 billion of annual therapy revenue is dependent on an efficient diagnostic testing ecosystem
DUNDALK, IRELAND and PARSIPPANY, NJ--(Marketwired - Dec 14, 2016) - Today, Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enabling pharmaceutical companies to leverage diagnostic testing, released its annual Pharma Readiness for Diagnostics Report. The report, which will be presented in a webinar today, is an assessment of 23 pharmaceutical and biotechnology companies with commercial therapies whose clinical and financial impact is highly dependent on the availability or efficiency of specific diagnostic tests.
"Those of us who see the untapped diagnostic opportunities across the treatment pathway have a key task in front of us - namely to quantify, analyze and communicate with evidence to pharma asset and financial leaders how $1 invested smartly in the diagnostic ecosystem will return $40-$60 in new therapy revenue and, more importantly, get the right patients on the right therapies," said Peter Keeling, CEO of Diaceutics. "Currently, the diagnostic ecosystem underpinning the pharmaceutical business model is opaque, yet it is such an essential driver in delivering the financial as well as clinical potential of precision medicine."
Key findings from this year's report include:
The Diaceutics report includes a comprehensive review and update of 23 pharmaceutical and biotechnology companies with at least one diagnostically-enabled therapy on the market or significant pipeline investment in biomarkers, and ranks them according to their potential to capitalize on opportunities in diagnostic test-driven markets. In this year's Diaceutics Pharma Readiness Index, the 23 companies fell into three categories:
"We expect Teva, Astellas and Daiichi to join the Fast Followers in 2017-18 based on their increased diagnostics focus in pipeline planning and their partnering trajectory," added Keeling. "A strong, early diagnostic-driven pipeline may result in GSK and Sanofi climbing up the index, but only from 2020 onwards."
The analyses included a detailed quantitative and qualitative review of each company based on publicly available information, interviews with industry leaders, and an evaluation and company ranking derived from Diaceutics' proprietary analysis of the data available on the 23 companies. Company analysis included a review of corporate structure and leadership, R&D structure, phase III pipeline, management and marketing of existing therapies, business deals and strategic partnerships and communications.
Highlights from the report will be delivered by Diaceutics' Ewelina Golebiewska, PhD, Data Analyst and Steve Vitale, Managing Director, during an online webinar December 14, 2017 from 11:00am - 12:00pm EST. For more information please visit: www.healthtech.com/diaceutics/which-pharma-companies-are-ready-for-precision-medicine.
About Diaceutics Group
Diaceutics, a global group of experts from the laboratory, diagnostics and pharmaceutical industries, enables pharmaceutical companies to leverage diagnostic testing. Through a real-time flow of testing data from a worldwide laboratory network, Diaceutics helps its clients understand and leverage the diagnostic landscape so they can successfully integrate testing into treatment pathways. For more information, please visit www.diaceutics.com or follow Diaceutics Group on Twitter, LinkedIn or YouTube.
Contact Information:
Media Contact
Colin Sanford
colin.sanford@diaceutics.com
(415) 870-9188